Statistical Health Monitoring Applied to a Metabolomic Study of Experimental Hepatocarcinogenesis: An Alternative Approach to Supervised Methods for the Identification of False Positives.
暂无分享,去创建一个
Luigi Atzori | Massimiliano Grosso | Andrea Perra | Francesco Del Carratore | L. Atzori | J. Griffin | A. Perra | M. Lussu | M. Grosso | Francesco Del Carratore | Milena Lussu | Marta Anna Kowalik | Julian Leether Griffin | M. Kowalik
[1] M. Turner,et al. A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis , 2014, Neurology.
[2] R. Brereton,et al. Partial least squares discriminant analysis: taking the magic away , 2014 .
[3] John C Lindon,et al. Statistical total correlation spectroscopy scaling for enhancement of metabolic information recovery in biological NMR spectra. , 2012, Analytical chemistry.
[4] Ara W. Darzi,et al. Metabolic phenotyping in clinical and surgical environments , 2012, Nature.
[5] R. Kauppinen,et al. 1H nuclear magnetic resonance spectroscopy characterisation of metabolic phenotypes in the medulloblastoma of the SMO transgenic mice , 2010, British Journal of Cancer.
[6] G. M. Ledda-Columbano,et al. Cell proliferation induced by triiodothyronine in rat liver is associated with nodule regression and reduction of hepatocellular carcinomas. , 2000, Cancer research.
[7] J. Griffin,et al. Increased hepatic oxidative metabolism distinguishes the action of Peroxisome proliferator-activated receptor δ from Peroxisome proliferator-activated receptor γ in the ob/ob mouse , 2009, Genome Medicine.
[8] S. Giordano,et al. MicroRNA/gene profiling unveils early molecular changes and NRF2 activation in a rat model recapitulating human HCC. , 2014 .
[9] Xin Lu,et al. A weighted relative difference accumulation algorithm for dynamic metabolomics data: long-term elevated bile acids are risk factors for hepatocellular carcinoma , 2015, Scientific Reports.
[10] T. Ebbels,et al. NMR-based metabolic profiling identifies biomarkers of liver regeneration following partial hepatectomy in the rat. , 2010, Journal of proteome research.
[11] J. Griffin,et al. Does Our Gut Microbiome Predict Cardiovascular Risk?: A Review of the Evidence From Metabolomics , 2015, Circulation. Cardiovascular genetics.
[12] L. Barberini,et al. Pharma-metabolomics in neonatology: is it a dream or a fact? , 2012, Current pharmaceutical design.
[13] J. Huse,et al. Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas. , 2013, Journal of neuropathology and experimental neurology.
[14] R. A. van den Berg,et al. Centering, scaling, and transformations: improving the biological information content of metabolomics data , 2006, BMC Genomics.
[15] C. Newgard,et al. Integrated metabolomics and genomics: systems approaches to biomarkers and mechanisms of cardiovascular disease. , 2015, Circulation. Cardiovascular genetics.
[16] Xuefeng Yan,et al. Chemical processes monitoring based on weighted principal component analysis and its application , 2012 .
[17] M. Rantalainen,et al. OPLS discriminant analysis: combining the strengths of PLS‐DA and SIMCA classification , 2006 .
[18] A. Chinnaiyan,et al. Magic angle spinning NMR-based metabolic profiling of head and neck squamous cell carcinoma tissues. , 2011, Journal of proteome research.
[19] Oliver A.H. Jones. Metabolomics and systems biology in human health and medicine. , 2014 .
[20] S. Williams,et al. A comparison of cell and tissue extraction techniques using high‐resolution 1H‐NMR spectroscopy , 2002, NMR in biomedicine.
[21] S. Joe Qin,et al. Statistical process monitoring: basics and beyond , 2003 .
[22] D. Wishart,et al. Translational biomarker discovery in clinical metabolomics: an introductory tutorial , 2012, Metabolomics.
[23] Age K. Smilde,et al. Generalized contribution plots in multivariate statistical process monitoring , 2000 .
[24] S. Joe Qin,et al. Analysis and generalization of fault diagnosis methods for process monitoring , 2011 .
[25] Peiyuan Yin,et al. Study of urinary steroid hormone disorders: difference between hepatocellular carcinoma in early stage and cirrhosis , 2014, Analytical and Bioanalytical Chemistry.
[26] A. Weljie,et al. Hypoxia-induced metabolic shifts in cancer cells: moving beyond the Warburg effect. , 2011, The international journal of biochemistry & cell biology.
[27] O. Feron,et al. Metabolic and mind shifts: from glucose to glutamine and acetate addictions in cancer , 2015, Current opinion in clinical nutrition and metabolic care.
[28] A. Smilde,et al. Assessing the statistical validity of proteomics based biomarkers. , 2007, Analytica chimica acta.
[29] Johan Trygg,et al. Chemometrics in metabonomics. , 2007, Journal of proteome research.
[30] D. Gauguier,et al. Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. , 2005, Analytical chemistry.
[31] Lutgarde M. C. Buydens,et al. Towards the Disease Biomarker in an Individual Patient Using Statistical Health Monitoring , 2014, PloS one.
[32] M. Pibiri,et al. Thyroid hormone receptor ligands induce regression of rat preneoplastic liver lesions causing their reversion to a differentiated phenotype , 2009, Hepatology.
[33] P. Ward,et al. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.
[34] S. Giordano,et al. MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC) , 2014, Hepatology.
[35] Theodora Kourti,et al. Statistical Process Control of Multivariate Processes , 1994 .